Dare Bioscience, Inc. (DARE): R&D Expense
$5.52M
Year ended 2025-12-31
$2.70M
Trailing 12 months to 2026-06-30
-43.1%
3-year compound annual growth
-23.3%
5-year compound annual growth
-14.3%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $5.52M | -61.4% | 2026-03-26, From 2025-01-01 |
| 2024-12-31 | $14.31M | -33.6% | 2026-03-26, From 2024-01-01 |
| 2023-12-31 | $21.54M | -28.3% | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | $30.04M | -1.9% | 2024-03-28, From 2022-01-01 |
| 2021-12-31 | $30.62M | +47.4% | 2023-03-30, From 2021-01-01 |
| 2020-12-31 | $20.77M | +143.0% | 2022-03-31, From 2020-01-01 |
| 2019-12-31 | $8.55M | +33.2% | 2021-03-30, From 2019-01-01 |
| 2018-12-31 | $6.41M | +551.3% | 2020-03-27, From 2018-01-01 |
| 2017-12-31 | $984.7K | n/m | 2019-04-01, From 2017-01-01 |
| 2016-12-31 | $72.7K | -99.7% | 2018-03-28, From 2016-01-01 |
| 2015-12-31 | $25.95M | +120.4% | 2017-06-13, From 2015-01-01 |
| 2014-12-31 | $11.77M | +21.4% | 2017-06-13, From 2014-01-01 |
| 2013-12-31 | $9.70M | -38.6% | 2016-03-10, From 2013-01-01 |
| 2012-12-31 | $15.81M | n/a | 2015-03-19, From 2012-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Dare Bioscience, Inc. (DARE) | 2025-12-31 | $5.52M | -61.4% |
| 60 Degrees Pharmaceuticals, Inc. (SXTP) | 2025-12-31 | $2.11M | -57.8% |
| Shattuck Labs, Inc. (STTK) | 2025-12-31 | $35.27M | -47.5% |
| Rafael Holdings, Inc. (RFL) | 2025-07-31 | $12.82M | +207.5% |
| Neuphoria Therapeutics Inc. (NEUP) | 2025-06-30 | $9.01M | -4.4% |
| Longeveron Inc. (LGVN) | 2025-12-31 | $12.04M | +48.0% |
| Rallybio Corp (RLYB) | 2025-12-31 | $19.60M | -52.8% |
| Vistagen Therapeutics, Inc. (VTGN) | 2026-03-31 | $54.97M | +39.6% |
| IGC Pharma, Inc. (IGC) | 2025-03-31 | $3.65M | -3.1% |
Compare DARE, SXTP, STTK, RFL side by side · Screen every company in Pharmaceutical Preparations ↗